Hemoperfusion with Seraph-100 in septic patients removes pathogens and improves clinical outcomes

Hemoperfusion (HP) represents a treatment option for sepsis. This study evaluated Seraph-100 in septic patients admitted to the intensive care unit (ICU) after cardiac surgery due to infective endocarditis (IE). Thirteen septic patients were enrolled and treated by Seraph-100 hemoperfusion. Fiftenne patients, not treated by HP, represented a control group. Pathogens were assessed before (T0) and after 4 h of HP treatment (T4). The difference between the two- quantification cycle (Cq) values (T0 and T4), namely ∆Cq at the polymerase chain reaction, was a surrogate marker of pathogen removal. The bacterial load decreased after Seraph-100 HP, with a mean ∆Cq values of 4.6 ± 2.4, as corroborated by conventional haemoculture's results. Field Emission Scanning Electron Microscopy analyses confirm the Seraph' adsorptive properties. Procalcitonin, C reactive protein and lactates significantly decreased, with a reduced ICU stay in the Seraph group. After HP, only 15% of patients had AKI requiring renal replacement therapy (RRT), significantly lower than that found in the control group (40%). The Seraph-100 HP induces a decrease of vasopressor doses, a hemodynamic stability and a reduction of AKI and RRT, improving the clinical course, reflected as a reduced ICU stay.